 Omega Diagnostics Group PLC
Annual Report and Group Financial Statements 2014
Fighting the battle 
against HIV and global 
health challenges Omega Diagnostics Group PLC Annual Report and Group Financial Statements 2014
About Us
34%
Revenue share
£5.2m
Revenue share
£4.0m
Revenue share
£2.4m
We’re committed 
to addressing global 
health challenges
Our mission is to improve human health and well-being through 
innovative diagnostic products and global partnerships.
Founded in 1987 by the current CEO Andrew Shepherd, the Omega business is focused on selling a wide 
range of specialist products, primarily in the immunoassay, in-vitro diagnostics (IVD) market within three 
segments: Allergy and autoimmune, Food intolerance and Infectious diseases.
Allergy and 
autoimmune
Main products:
 −Allergozyme
 −Allergodip
 − Genesis Elisa
45% 21%
Food  
intolerance
Main products:
 −Genarrayt
®
 Microarray
 − Food Detective
 − Foodprint service
Infectious 
diseases
Main products:
 − Immutrep Syphilis
 − Micropath Bacterial tests
 − Dengue Elisa
p18
Financial Review
p8
Our Core Markets 01
Omega Diagnostics Group PLC Annual Report and Group Financial Statements 2014
Overview
Contents Financial Highlights
Overview
IFC About Us
01 Financial Highlights
02 Our Year at a Glance
04 Chairman’s Statement
Strategic Report
06 Our Business Model
08 Our Core Markets
10 Our Strategy
11 Key Performance Indicators
12 Risks and Risk Management
14 Chief Executive’s Review
16 Product Case Study
18 Financial Review
Governance
20 Board of Directors
21 Senior Management Team
22 Corporate Governance Report
24 Advisers
25 Directors’ Report
27  Directors’ Remuneration Report
29  Statement of Directors’ Responsibilities
Financial Statements
30 Independent Auditors’ Report
31  Consolidated Statement of Comprehensive Income
31 Adjusted Proﬁt Before Taxation
32 Consolidated Balance Sheet
33  Consolidated Statement of Changes in Equity
34 Consolidated Cash Flow Statement
35 Company Balance Sheet
36 Company Statement of Changes in Equity
37 Company Cash Flow Statement
38 Notes to the Financial Statements
63 Notice of Annual General Meeting
64 Notes to the Notice of Annual General Meeting
11.1
11.3
11.6
2012 2013 2014
Sales (£m)
£11.6m 3%
7.0
7.1
7.4
2012 2013 2014
Gross proﬁt (£m)
£7.4m 5%
1.0
0.8
1.1
2012 2013 2014
Adjusted proﬁt before tax (£m)
£1.1m 41%
63.0
62.6
63.6
2012 2013 2014
Gross proﬁt (%)
63.6% 1ppt
Find up-to-date information at  
www.omegadiagnostics.com
